Crizanlizumab
http://dbpedia.org/resource/Crizanlizumab an entity of type: Thing
Кризанлизумаб — моноклональное антитело для лечения серповидноклеточной анемии. Одобрен для применения: США (ноябрь 2019).
rdf:langString
Crizanlizumab, sold under the brand name Adakveo & Ryverna both by Novartis, is a monoclonal antibody medication that binds to P-selectin. It is a drug used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia. Vaso-occlusive crisis is a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells (red cells are usually round and flexible, but sometimes many red cells in a person with sickle cell anemia will become rigid and crescent-shaped due to polymerization of hemoglobin).
rdf:langString
rdf:langString
Crizanlizumab
rdf:langString
Кризанлизумаб
xsd:integer
52481577
xsd:integer
1090917138
rdf:langString
AX01
rdf:langString
B06
xsd:integer
6458
xsd:integer
1690318
rdf:langString
none
rdf:langString
DB15271
xsd:integer
9948
rdf:langString
D11480
rdf:langString
Rx-only
rdf:langString
a620010
xsd:integer
1712
xsd:integer
2050
xsd:integer
58
rdf:langString
zu
rdf:langString
SEG101, SelG1, crizanlizumab-tmca
rdf:langString
Adakveo
rdf:langString
mab
rdf:langString
L7451S9126
rdf:langString
Crizanlizumab, sold under the brand name Adakveo & Ryverna both by Novartis, is a monoclonal antibody medication that binds to P-selectin. It is a drug used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia. Vaso-occlusive crisis is a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells (red cells are usually round and flexible, but sometimes many red cells in a person with sickle cell anemia will become rigid and crescent-shaped due to polymerization of hemoglobin). The result of the Phase II SUSTAIN clinical trial was published in December 2016, and in November 2019, crizanlizumab-tmca was approved in the United States. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
rdf:langString
Кризанлизумаб — моноклональное антитело для лечения серповидноклеточной анемии. Одобрен для применения: США (ноябрь 2019).
rdf:langString
Crizanlizumab
rdf:langString
S4
rdf:langString
Rx-only
rdf:langString
Adakveo
rdf:langString
mab
rdf:langString
B1
xsd:nonNegativeInteger
8998
rdf:langString
Adakveo
xsd:string
1690318-25-2
xsd:string
DB15271
xsd:string
L7451S9126
xsd:string
D11480
xsd:string
a620010